Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current trends in pleurodesis

F Rodriguez-Panadero1

  • 1El Mirador, Tomares, Sevilla, Spain.

Current Opinion in Pulmonary Medicine
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Pleurodesis prevents fluid or air buildup in the pleural space. Talc is preferred for malignant effusions, while VATS is ideal for pneumothorax, optimizing patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The case for performing pleural biopsies for the aetiological diagnosis of exudates. Yes.

Revista clinica espanola·2017
Same author

Interleukin-8 activates coagulation and correlates with survival after talc pleurodesis.

The European respiratory journal·2009
Same author

Pleurodesis by talc poudrage under simple medical thoracoscopy: an international opinion.

Thorax·2009
Same author

[Accuracy of pleural fluid cytology in malignant effusions].

Anales de medicina interna (Madrid, Spain : 1984)·2008
Same author

Thoracoscopy: general overview and place in the diagnosis and management of pleural effusion.

The European respiratory journal·2006
Same author

The neutrophilic and fibrinolytic response to talc can predict the outcome of pleurodesis.

The European respiratory journal·2006
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
Same journal

Advancing lung transplantation: current challenges and future directions.

Current opinion in pulmonary medicine·2026
Same journal

Association between upper airway obstruction and pulmonary hypertension in children with Down syndrome.

Current opinion in pulmonary medicine·2026
Same journal

Molecular mechanisms of environmental risk factors for interstitial lung disease.

Current opinion in pulmonary medicine·2026
See all related articles

Area of Science:

  • Thoracic Surgery
  • Pulmonology

Background:

  • Pleurodesis aims to fuse visceral and parietal pleura, preventing pleural space fluid or air accumulation.
  • Primary indications include malignant effusions and pneumothorax.

Purpose of the Study:

  • To review the indications, techniques, and outcomes of pleurodesis.
  • To highlight optimal agent and technique selection for specific conditions.

Main Methods:

  • Review of current literature on pleurodesis for malignant effusions and pneumothorax.
  • Analysis of criteria for patient selection, including lung reexpansibility and survival.
  • Evaluation of sclerosing agents (talc) and surgical techniques (VATS).

Main Results:

  • Low pleural fluid pH (<7.20) predicts trapped lung and short survival in malignant effusions.

Related Experiment Videos

  • Talc is the preferred agent for malignant effusions; VATS is favored for pneumothorax, especially in young patients.
  • Proper technique, including drainage size and suction rate, is critical for success and complication prevention.

    • Conclusions:

    • Pleurodesis is a key intervention for malignant effusions and pneumothorax.
    • Tailoring the technique and agent to the patient's condition is essential for optimal results.
    • Prophylactic heparin may be considered for malignant effusion palliation to prevent coagulation activation.